A new campaign and proposed law to rein in pharma sales activities in China indicates a new round of regulatory tightening as companies start to resume commercial operations post the coronavirus outbreak.

Latest regulation aiming to rein in medical sales indicated new round of regulatory tightening in China as pharma firms resume post-coronavirus commercial operations.

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.